Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Retraction notice: Odanacatib for the treatment of postmenopausal osteoporosis
56(7):3012-23
lodoxamide inhibits compound 48/80-induced histamine release and ionophore-induced 45Ca influx with associated histamine release in purified rat peritoneal mast cells[1]
5-difluorophenyl)-5-(4
({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid
SGX-523 - CAS# 1022150-57-7 Size:Solid 10 mg Retraction notice: Odanacatib for theSGX523 is a novel, ATP competitive kinase inhibitor remarkable for its exquisite selectivity for MET. SGX523 potently inhibited MET with an IC50 of 4 nmol L and is >1,000 fold selective versus the >200 fold selectivity of other protein kinases tested in biochemical assays. Crystallographic study revealed that SGX523 stabilizes MET in a unique inactive conformation that is inaccessible to other protein kinases, suggesting an explanation for the